Dynamic Monitoring of Ongoing Clinical Trials

References

• Bauer, P., and Kohne, K. (1994), “Evaluation of Experiments With Adaptive Interim Analyses,” Biometrics, 50, 1029–1041. DOI: 10.2307/2533441.
   PubMed Web of Science ®Google Scholar
• Bowden, J., and Mander, A. (2014), “A Review and Re-Interpretation of a Group-Sequential Approach to Sample Size Re-Estimation in Two-Stage Trials,” Pharmaceutical Statistics, 13, 163–172. DOI: 10.1002/pst.1613.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research Food and Drug Administration (2019), “Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry.”
   Google Scholar
• Chen, Y. H., DeMets, D. L., and Lan, K. K. G. (2004), “Increasing the Sample Size When the Unblinded Interim Result Is Promising,” Statistics in Medicine, 23, 1023–1038. DOI: 10.1002/sim.1688.
   PubMed Web of Science ®Google Scholar
• Cui, L., Hung, H. M., and Wang, S. J. (1999), “Modification of Sample Size in Group Sequential Clinical Trials,” Biometrics, 55, 853–857. DOI: 10.1111/j.0006-341x.1999.00853.x.
   PubMed Web of Science ®Google Scholar
• Gao, P., Liu, L. Y., and Mehta, C. (2013), “Exact Inference for Adaptive Group Sequential Designs,” Statistics in Medicine, 32, 3991–4005. DOI: 10.1002/sim.5847.
   PubMed Web of Science ®Google Scholar
• Gao, P., Ware, J. H., and Mehta, C. (2008), “Sample Size Re-Estimation for Adaptive Sequential Designs,” Journal of Biopharmaceutical Statistics, 18, 1184–1196. DOI: 10.1080/10543400802369053.
   PubMed Web of Science ®Google Scholar
• Gould, A. L., and Shih, W. J. (1992), “Sample Size Re-Estimation Without Unblinding for Normally Distributed Outcomes With Unknown Variance,” Communications in Statistics—Theory and Methods, 21, 2833–2853. DOI: 10.1080/03610929208830947.
   Web of Science ®Google Scholar
• Herson, J., and Wittes, J. (1993), “The Use of Interim Analysis for Sample Size Adjustment,” Drug Information Journal, 27, 753–760. DOI: 10.1177/009286159302700317.
   Google Scholar
• Lan, K. K. G., and DeMets, D. L. (1983), “Discrete Sequential Boundaries for Clinical Trials,” Biometrika, 70, 659–663. DOI: 10.2307/2336502.
   Web of Science ®Google Scholar
• Lan, K. K. G., and DeMets, D. L. (1989), “Changing Frequency of Interim Analysis in Sequential Monitoring,” Biometrics, 45, 1017–1020.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G., Rosenberger, W. F., and Lachin, J. M. (1993), “Use of Spending Functions for Occasional or Continuous Monitoring of Data in Clinical Trials,” Statistics in Medicine, 12, 2219–2231. DOI: 10.1002/sim.4780122307.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G., Simon, R., and Halperin, M. (1982), “Stochastically Curtailed Tests in Long-Term Clinical Trials,” Communications in Statistics, Part C: Sequential Analysis, 1, 207–219.
   Google Scholar
• Lan, K. K. G., and Wittes, J. (1988), “The B-Value: A Tool for Monitoring Data,” Biometrics, 44, 579–585. DOI: 10.2307/2531870.
   PubMed Web of Science ®Google Scholar
• Li, G., Shih, W. J., Xie, T., and Lu, J. (2002), “A Sample Size Adjustment Procedure for Clinical Trials Based on Conditional Power,” Biostatistics, 3, 277–287. DOI: 10.1093/biostatistics/3.2.277.
   PubMed Web of Science ®Google Scholar
• Mehta, C. R., and Pocock, S. J. (2011), “Adaptive Increase in Sample Size When Interim Results Are Promising: A Practical Guide With Examples,” Statistics in Medicine, 30, 3267–3284. DOI: 10.1002/sim.4102.
   PubMed Web of Science ®Google Scholar
• Müller, H. H., and Schäfer, H. (2001), “Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches,” Biometrics, 57, 886–891. DOI: 10.1111/j.0006-341x.2001.00886.x.
   PubMed Web of Science ®Google Scholar
• O’Brien, P. C., and Fleming, T. R. (1979), “A Multiple Testing Procedure for Clinical Trials,” Biometrics, 35, 549–556. DOI: 10.2307/2530245.
   PubMed Web of Science ®Google Scholar
• Pocock, S. J. (1977), “Group Sequential Methods in the Design and Analysis of Clinical Trials,” Biometrika, 64, 191–199. DOI: 10.1093/biomet/64.2.191.
   Web of Science ®Google Scholar
• Posch, M., Koenig, F., Branson, M., Brannath, W., Dunger-Baldauf, C., and Bauer, P. (2005), “Testing and Estimation in Flexible Group Sequential Designs With Adaptive Treatment Selection,” Statistics in Medicine, 24, 3697–3714. DOI: 10.1002/sim.2389.
   PubMed Web of Science ®Google Scholar
• Proschan, M. A. (1999), “A Multiple Comparison Procedure for Three- and Four-Armed Controlled Clinical Trials,” Statistics in Medicine, 18: 787–798. DOI: 10.1002/(SICI)1097-0258(19990415)18:7<787::AID-SIM77>3.0.CO;2-M.
   PubMed Web of Science ®Google Scholar
• Proschan, M. A., and Hunsberger, S. A. (1995), “Designed Extension of Studies Based on Conditional Power,” Biometrics, 51, 1315–1324. DOI: 10.2307/2533262.
   PubMed Web of Science ®Google Scholar
• Proschan, M. A., and Lan, K. K. G. (2012), “Spending Functions and Continuous-Monitoring Boundaries,” Statistics in Medicine, 31, 3024–3030. DOI: 10.1002/sim.5481.
   PubMed Web of Science ®Google Scholar
• Proschan, M. A., Lan, K. K. G., and Wittes, J. (2006), Statistical Monitoring of Clinical Trials—A Unified Approach, New York: Springer.
   Google Scholar
• Scharfstein, D. O., Tsiatis, A. A., and Robins, J. M. (1997), “Semiparametric Efficiency and Its Implication on the Design and Analysis of Group-Sequential Studies,” Journal of the American Statistical Association, 92, 1342–1350. DOI: 10.1080/01621459.1997.10473655.
   Web of Science ®Google Scholar
• Shih, W. J. (1992), “Sample Size Reestimation in Clinical Trials,” in Biopharmaceutical Sequential Statistical Applications, ed. K. Peace, New York: Marcel Dekker, Inc., pp. 285–301.
   Google Scholar
• Shih, W. J. (2001), “Commentary: Sample Size Re-Estimation—Journey for a Decade,” Statistics in Medicine, 20, 515–518.
   PubMed Web of Science ®Google Scholar
• Shih, W. J., Li, G., and Wang, Y. (2016), “Methods for Flexible Sample-Size Design in Clinical Trials: Likelihood, Weighted, Dual Test, and Promising Zone Approaches,” Contemporary Clinical Trials, 47, 40–48. DOI: 10.1016/j.cct.2015.12.007.
   PubMed Web of Science ®Google Scholar
• Shih, W. J., Yao, C., and Xie, T. (2020), “Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients With COVID-19 During the Pandemic Crisis,” Therapeutic Innovation & Regulatory Science, 54:1236–1255, DOI: 10.1007/s43441-020-00159-7.
   PubMed Web of Science ®Google Scholar
• Tsiatis, A. (1982), “Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Analysis,” Journal of the American Statistical Association, 77, 855–861. DOI: 10.1080/01621459.1982.10477898.
   Web of Science ®Google Scholar
• Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., and Hu, Y. (2020), “Remdesivir in Adults With Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial,” Lancet, 395, 1569–1578, DOI: 10.1016/S0140-6736(20)31022-9.
   PubMed Web of Science ®Google Scholar
• Wittes, J., and Brittain, E. (1990), “The Role of Internal Pilot Studies in Increasing the Efficiency of Clinical Trials,” Statistics in Medicine, 9, 65–72. DOI: 10.1002/sim.4780090113.
   PubMed Web of Science ®Google Scholar
• Xi, D., Gallo, P., and Ohlssen, D. (2017), “On the Optimal Timing of Futility Interim Analyses,” Statistics in Biopharmaceutical Research, 9, 293–301. DOI: 10.1080/19466315.2017.1340906.
   Web of Science ®Google Scholar